Themis Bioscience’s Raises up to EUR 10 Million in Series B
Themis Bioscience announced the first closing of EUR 7 Million in a Series B financing of up to EUR 10 Million, led by new investor Wellington Partners. Existing investors Ventech and Omnes Capital (formerly Crédit Agricole Private Equity) also participated in the round. Dr Regina Hodits, General Partner at Wellington Partners will join Themis’ Board.
With their Chikungunya fever vaccine candidate demonstrating good immunogenicity, safety and tolerability in a Phase 1 clinical trial, Themis plans to progress this lead product candidate into clinical phase II trials. In parallel the company will advance its other promising development pipeline in collaboration with the Institut Pasteur in Paris, originators of the measles vector platform licensed to Themis.
Themis also announced the new structure of its Board with Dr Gerd Zettlmeissl being named Chairman of the Board. Dr Zettlmeissl spent more than 20 years in executive positions in the international pharmaceutical and vaccine biotech industry. From 2005 until May 2011 he served as CEO of Intercell AG. Experienced biotech and vaccine industry expert Dr Jean-Paul Prieels will join as a new member the expanded board. He served as Senior Vice President of R&D at GlaxoSmithKline Biologicals until January 2011, led GSK’s global vaccine R&D development activities and was Head of Research for GSK Vaccines.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
